Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia. It was developed by Bluebird Bio...
21 KB (1,463 words) - 07:11, 6 August 2024
company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia...
15 KB (1,409 words) - 21:01, 17 October 2024
million in the United States for its one-time treatment Zynteglo (betibeglogene autotemcel). Gene editing therapies aimed at increasing fetal hemoglobin production...
57 KB (5,458 words) - 22:49, 19 September 2024
The most positive results tend to occur with very young people. Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the...
67 KB (7,132 words) - 02:15, 19 October 2024
B06AX01 Crizanlizumab B06AX02 Betibeglogene autotemcel B06AX03 Voxelotor B06AX04 Mitapivat B06AX05 Exagamglogene autotemcel "ATC (Anatomical Therapeutic...
960 bytes (213 words) - 02:49, 18 December 2023
making it the most expensive drug ever. In May, the EMA approved betibeglogene autotemcel (Zynteglo) for treating beta thalassemia for people twelve years...
179 KB (18,426 words) - 01:50, 21 November 2024
RMAT designated drugs include the novel CAR-T therapy Kymriah and betibeglogene autotemcel for beta thalassemia. As of 31 March 2021, 62 requests for RMAT...
28 KB (1,584 words) - 03:45, 11 August 2024
lymphoma Beremagene geperpavec (Vyjuvek): treatment of wounds. Betibeglogene autotemcel (Zynteglo): treatment for beta thalassemia Brexucabtagene autoleucel...
11 KB (834 words) - 06:28, 10 November 2024
and mortality 7%. The best results are with very young people. Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the...
44 KB (4,881 words) - 16:56, 27 October 2024
arylsulfatase A (ARSA) gene (European approval granted 2020). Betibeglogene autotemcel (branded as Zynteglo) for the treatment of transfusion-dependent...
78 KB (8,788 words) - 19:06, 6 August 2024